Skip to main content

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

Generic: neomycin sulfate, polymyxin b sulfate and gramicidin

Verified·Apr 23, 2026
NDC
24208-790
RxCUI
310594
Route
OPHTHALMIC
ICD-10 indication
H10.00

Affordability Check

How much will you actually pay for NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN?

In 30 seconds, see every legitimate way to afford NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

What is this medication? Neomycin, polymyxin B, and gramicidin is a prescription combination antibiotic medication primarily used to treat bacterial infections of the eye. This ophthalmic solution is commonly prescribed for conditions such as conjunctivitis, which is often referred to as pink eye, and other superficial infections affecting the cornea or eyelids. By combining three different antibiotics, the medication provides a broad spectrum of activity that targets a wide range of bacteria, helping to clear the infection and reduce symptoms like redness, swelling, and discharge. This medication should be used exactly as prescribed by a healthcare provider, typically involving placing drops into the affected eye at regular intervals. It is specifically formulated to treat infections caused by bacteria and will not be effective against viral or fungal eye conditions. To ensure the infection is completely eradicated and to prevent the development of antibiotic resistance, patients must complete the full course of treatment even if their symptoms appear to improve after just a few days.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN. Official source: DailyMed (NLM) · Label effective Sep 18, 2024

Indications and usage
INDICATIONS AND USAGE Neomycin and polymyxin B sulfates and gramicidin ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.
Dosage and administration
DOSAGE AND ADMINISTRATION Instill one or two drops into the affected eye every 4 hours for 7 to 10 days. In severe infections, dosage may be increased to as much as two drops every hour. donot
Contraindications
CONTRAINDICATIONS This product is contraindicated in those persons who have shown hypersensitivity to any of its components.
Warnings
WARNINGS NOT FOR INJECTION INTO THE EYE. This product should never be directly introduced into the anterior chamber of the eye or injected subconjunctivally. Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical antibiotics is not known. The manifestations of sensitization to topical antibiotics are usually itching, reddening and edema of the conjunctiva and eyelid. A sensitization reaction may manifest simply as a failure to heal. During long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. Symptoms usually subside quickly on withdrawing the medication. Applications of products containing these ingredients should be avoided for the patient thereafter (see PRECAUTIONS : Error! Hyperlink reference not valid. ).
Adverse reactions
ADVERSE REACTIONS Adverse reactions have occurred with the anti-infective components of this product. The exact incidence is not known. Reactions occurring most often are allergic reactions including itching, swelling, and conjunctival erythema (see WARNINGS ). More serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. Local irritation on instillation has also been reported. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Use in pregnancy
Pregnancy: Teratogenic Effects Adequate animal reproductive studies have not been conducted with neomycin, polymyxin B, or gramicidin. It is also not known whether this product can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This product should be given to a pregnant woman only if clearly needed.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-04-30).

Covered by plans

74%

4,100 of 5,509 plans

Most common tier

Tier 3

On 40% of covering formularies

Prior authorization required

0%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)65
20%
Tier 2 (generic)117
36%
Tier 3 (preferred brand)129
40%
Tier 4 (non-preferred brand)13
4%

Step therapy: 0% of formularies

Quantity limits: 10% of formularies

Coverage breadth: 324 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.